Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/UCB's Phase III Success May Not Be Enough To Top Osteoporosis Rivals

This article was originally published in The Pink Sheet Daily

Executive Summary

Romosozumab shows ability to reduce risk of spinal fractures, but misses a secondary endpoint on nonvertebral fracture risk reduction.

Advertisement

Related Content

Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Regenerating Interest In Novel Drugs For Postmenopausal Osteoporosis

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel